EWTX — Edgewise Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1710072 ·
Last close
$44.72
Market Cap
$4.86B
52W High
$48.40
52W Low
$30.84
ADV30
1,192,998
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -61,943,000 | -57,327,000 | 479,688,000 | 72,319,000 | 31,611,000 |
| Mar 2026 | 0 | — | -54,115,000 | -49,013,000 | 518,522,000 | 33,211,000 | 25,319,000 |
| Dec 2025 | 0 | — | -55,979,000 | -50,216,000 | 552,603,000 | 61,148,000 | 30,346,000 |
| Sep 2025 | 0 | — | -46,858,000 | -40,666,000 | 583,466,000 | 46,003,000 | 24,819,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-158,380,000
Investing CF
$166,401,000
Financing CF
$20,894,000
CapEx
$-454,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.85
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-652,711,000
Inventory
—
Receivables
—
ST Investments
$388,390,000
EBIT TTM
$-218,895,000
Pretax Income TTM
$-197,222,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -191,406,000 | -167,795,000 | 552,603,000 | 30,346,000 | — | -143,816,000 |
| Dec 2024 | 0 | -158,832,000 | -133,813,000 | 486,817,000 | 27,601,000 | — | -109,028,000 |
| Dec 2023 | 0 | -114,357,000 | -100,163,000 | 340,035,000 | 21,205,000 | — | -91,948,000 |
| Dec 2022 | 0 | -71,658,000 | -67,640,000 | 367,101,000 | 20,385,000 | — | -52,635,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.82
Max Pain — expiry 2026-09-18
max pain strike: $45.00 · spot: $45.33 · call oi: 10,251 · put oi: 255
Expected Move to 2026-09-18:
±$6.25
(13.79%) —
implied range
$39.08 –
$51.58
· ATM straddle on $45.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | $4.85B | $25.99 | — |
| GIFLF | Grifols SA | $4.97B | $11.76 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $5.08B | $29.65 | — |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | $61.15 | — |
| GIKLY | Grifols SA | $4.31B | $5.10 | — |
News headlines (Yahoo Finance, 1h cache)
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-06 12:00 · Yahoo
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
2026-07-13 12:30 · Yahoo
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
2026-07-13 12:30 · Yahoo
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
2026-07-01 12:00 · Yahoo
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
2026-06-25 12:41 · Yahoo
Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says
2026-06-17 15:02 · Yahoo
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
2026-06-16 20:06 · Yahoo
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall
2026-06-16 12:44 · Yahoo
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
2026-06-16 11:00 · Yahoo
Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarr
2026-08-17 14:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.